Clinical trials: Age Related Maculopathy
Exudative Age-related Macular Degeneration
Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
•Purpose: Age-related Macular Degeneration ( AMD) is the leading cause of blindness and visual impairment in industrialized countries.
- Trial name
- NCT01404845
- Testing
- Nutrof Total, food supplement without Lutein and Zeaxanthin
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Affordance
Macular Degeneration, Cataract
Age-Related Eye Disease Study (AREDS)
To assess the clinical course, prognosis, and risk factors of age-related macular degeneration (AMD) and cataract. To evaluate, in randomized clinical trials, the effects of pharmacologic doses of (1) antioxidants and zinc on the…
- Conditions
- Macular Degeneration, Cataract, Lens Opacities
- Trial name
- NCT00000145
- Testing
- Antioxidants, Zinc, Antioxidants and zinc
- Volunteers
- 4,757 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD)
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
The study will explore the impact of photobiomodulation (PBM), pulsating at frequencies of red (660nm) and near-infrared (810nm)(NIR), concurrent with a ketogenic dietary protocol (serum ketones @ .5 - 2.0 mmol/L) to mediate…
- Conditions
- Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
- Trial name
- NCT03859245
- Testing
- Photobiomodulation, Ketogenic diet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Retinitis Pigmentosa, Choroideremia
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.
- Conditions
- Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease
- Trial name
- NCT06375239
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Ray Therapeutics, Inc.
Neovascular (Wet) AMD
Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
- Trial name
- NCT06550011
- Testing
- ABI-110 Low Dose, ABI-110 Medium Dose, ABI-110 High Dose
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Avirmax Biopharma Inc
Neovascular Age-related Macular Degeneration(nAMD)
Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD) is one of the main causes of irreversible vision loss in the elderly, characterized by neovascularization and vascular leakage in the macular area, ultimately leading to damage…
- Trial name
- NCT07088445
- Testing
- Faricimab
- Volunteers
- 35 people
- Sponsor
- Hui Peng
Age Related Macular Degeneration
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
This study is designed to compare the effect of combined intravitreal Bevacizumab and Propranolol injection versus Bevacizumab monotherapy in patients with Age Related Macular Degeneration.
- Trial name
- NCT03609307
- Testing
- Combined Intravitreal bevacizumab and propranolol, Intravitreal bevacizumab
- Where
- Iran
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Age-Related Macular Degeneration
The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain
Patients are already receiving an intravitreal injection as a standard of care, but they are consenting to receiving a loteprednol drop following the intravitreal injection.
- Trial name
- NCT05542381
- Testing
- Loteprednol Etabonate Ophthalmic Gel [Lotemax], Refresh Lubricant Eye Drops [Artificial Tears]
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Virginia Polytechnic Institute and State University
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval (PTI) to participants…
- Trial name
- AVONELLE-X (NCT04777201)
- Testing
- Faricimab, Anti-VEGF Therapy
- Where
- 251 sites in United States, Argentina and 25 more
- Volunteers
- 1,036 people
- Sponsor
- Hoffmann-La Roche
Neovascular (Wet) Age-Related Macular Degeneration
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.
- Trial name
- NCT05197270
- Testing
- 4D-150 IVT, Aflibercept IVT
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 215 people
- Sponsor
- 4D Molecular Therapeutics
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by the definition of disease activity, which determines the treatment interval until the next injection.
- Trial name
- FLUID (NCT01972789)
- Testing
- Ranibizumab
- Where
- 16 sites in Australia
- Volunteers
- 349 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration
A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses
This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).
- Trial name
- NCT07330674
- Testing
- ABF-101
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Aptabio Therapeutics, Inc.
Exudative Age-related Macular Degeneration
Intravitreal Aflibercept for Submacular Hemorrhage
The prognosis of exudative age-related macular degeneration (AMD) accompanied by submacular hemorrhage is generally poor. A recently developed anti-VEGF agent eyeliaTM is also a useful treatment option for exudative AMD.
- Trial name
- NCT03169660
- Testing
- Vascular endothelial growth factor trap-eye
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Kim's Eye Hospital
Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD)
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
The purpose of this research study is to observe the patient's clinical care and how EYLEA® HD is used as a treatment in real-world settings.
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment
- Trial name
- SPECTRUM-US (NCT06398080)
- Testing
- aflibercept 8 mg
- Sponsor
- Regeneron Pharmaceuticals
Macular Degeneration, Retinal Vein Occlusion
Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders
This study will evaluate the safety and effectiveness of a new formulation of triamcinolone acetonide for the treatment of retinal blood vessel disorders.
- Trial name
- NCT00071227
- Testing
- Triamcinolone Acetonide (TAC-PF)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Eye Institute (NEI)
Geographic Atrophy, Age Related Macular Degeneration
Phase 2/3 Study of ALK-001 in Geographic Atrophy
This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD).
- Conditions
- Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic
- Trial name
- SAGA (NCT03845582)
- Testing
- ALK-001 oral capsule
- Where
- 24 sites in United States
- Volunteers
- 200 people
- Sponsor
- Alkeus Pharmaceuticals, Inc.
Cataract, Age-related Cataract
Association Between Light Spectrum and Survival After Cataract Surgery
This study was a retrospective observational cohort analysis of subjects aged 65 years and older, who underwent bilateral cataract surgery within a single (15 hospital) healthcare system, to determine the association between type…
- Conditions
- Cataract, Age-related Cataract, Circadian Rhythm Disorders, Glaucoma
- Trial name
- NCT04187157
- Testing
- Blue-light filtering intraocular lens, Conventional intraocular lens
- Where
- United States
- Volunteers
- 10,192 people
- Sponsor
- University of Pittsburgh
Neovascular Age-related Macular Degeneration
Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration
This is a Phase 1 study, first-in-human (FIH), open label study to evaluate the safety, tolerability and identify the maximum tolerated dose (MTD) of PMC-403 and determine the recommended phase 2 dose (RP2D).
- Trial name
- NCT05953012
- Testing
- PMC-403
- Where
- 4 sites in South Korea
- Volunteers
- 17 people
- Sponsor
- PharmAbcine
Age-related Macular Degeneration
Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and…
- Trial name
- NCT06458595
- Testing
- KH658
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
Age-related Macular Degeneration, Diabetic Macular Edema
Observational Study of Vision Improvement in Patients With Retinal Disorders
The purpose of this study is to assess the vision improvement achieved by patients with retinal disorders who received corneal treatments by a low vision aid device.
- Trial name
- NCT04693702
- Testing
- Corneal treatment by a low vision aid device
- Where
- Canada
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.